HomeBiotechnology mRNA Vaccines and Therapeutics Market Trends, Growth, & Share-2031
mRNA Vaccines and Therapeutics Market Size, Share & Trends Analysis Report By Applications (COVID-19 mRNA vaccines, Non-COVID-19 mRNA vaccines), By mRNA type (COVID-19, Non-COVID-19) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2023-2031
Global mRNA Vaccines and Therapeutics Market Size Analysis
Global mRNA Vaccines and Therapeutics Market Introduction
By Applications
Introduction
Applications By Value
COVID-19 mRNA vaccines
By Value
Commercialized Vaccines
Commercialized Vaccines By Value
Pipeline Vaccines
Pipeline Vaccines By Value
Non-COVID-19 mRNA vaccines
By Value
Oncology
Oncology By Value
Infectious Diseases
Infectious Diseases By Value
Other Diseases
Other Diseases By Value
By mRNA type
Introduction
mRNA type By Value
COVID-19
By Value
Nucleoside-Modified mRNA (modRNA)
Nucleoside-Modified mRNA (modRNA) By Value
Unmodified mRNA
Unmodified mRNA By Value
Self-Amplifying mRNA
Self-Amplifying mRNA By Value
Non-COVID-19
By Value
Nucleoside-Modified mRNA (modRNA)
Nucleoside-Modified mRNA (modRNA) By Value
Unmodified mRNA
Unmodified mRNA By Value
Self-Amplifying mRNA)
Self-Amplifying mRNA) By Value
North America Market Analysis
Introduction
By Applications
Introduction
Applications By Value
COVID-19 mRNA vaccines
By Value
Commercialized Vaccines
Commercialized Vaccines By Value
Pipeline Vaccines
Pipeline Vaccines By Value
Non-COVID-19 mRNA vaccines
By Value
Oncology
Oncology By Value
Infectious Diseases
Infectious Diseases By Value
Other Diseases
Other Diseases By Value
By mRNA type
Introduction
mRNA type By Value
COVID-19
By Value
Nucleoside-Modified mRNA (modRNA)
Nucleoside-Modified mRNA (modRNA) By Value
Unmodified mRNA
Unmodified mRNA By Value
Self-Amplifying mRNA
Self-Amplifying mRNA By Value
Non-COVID-19
By Value
Nucleoside-Modified mRNA (modRNA)
Nucleoside-Modified mRNA (modRNA) By Value
Unmodified mRNA
Unmodified mRNA By Value
Self-Amplifying mRNA)
Self-Amplifying mRNA) By Value
U.S.
By Applications
Introduction
Applications By Value
COVID-19 mRNA vaccines
By Value
Commercialized Vaccines
Commercialized Vaccines By Value
Pipeline Vaccines
Pipeline Vaccines By Value
Non-COVID-19 mRNA vaccines
By Value
Oncology
Oncology By Value
Infectious Diseases
Infectious Diseases By Value
Other Diseases
Other Diseases By Value
By mRNA type
Introduction
mRNA type By Value
COVID-19
By Value
Nucleoside-Modified mRNA (modRNA)
Nucleoside-Modified mRNA (modRNA) By Value
Unmodified mRNA
Unmodified mRNA By Value
Self-Amplifying mRNA
Self-Amplifying mRNA By Value
Non-COVID-19
By Value
Nucleoside-Modified mRNA (modRNA)
Nucleoside-Modified mRNA (modRNA) By Value
Unmodified mRNA
Unmodified mRNA By Value
Self-Amplifying mRNA)
Self-Amplifying mRNA) By Value
Canada
Europe Market Analysis
Introduction
By Applications
Introduction
Applications By Value
COVID-19 mRNA vaccines
By Value
Commercialized Vaccines
Commercialized Vaccines By Value
Pipeline Vaccines
Pipeline Vaccines By Value
Non-COVID-19 mRNA vaccines
By Value
Oncology
Oncology By Value
Infectious Diseases
Infectious Diseases By Value
Other Diseases
Other Diseases By Value
By mRNA type
Introduction
mRNA type By Value
COVID-19
By Value
Nucleoside-Modified mRNA (modRNA)
Nucleoside-Modified mRNA (modRNA) By Value
Unmodified mRNA
Unmodified mRNA By Value
Self-Amplifying mRNA
Self-Amplifying mRNA By Value
Non-COVID-19
By Value
Nucleoside-Modified mRNA (modRNA)
Nucleoside-Modified mRNA (modRNA) By Value
Unmodified mRNA
Unmodified mRNA By Value
Self-Amplifying mRNA)
Self-Amplifying mRNA) By Value
U.K.
By Applications
Introduction
Applications By Value
COVID-19 mRNA vaccines
By Value
Commercialized Vaccines
Commercialized Vaccines By Value
Pipeline Vaccines
Pipeline Vaccines By Value
Non-COVID-19 mRNA vaccines
By Value
Oncology
Oncology By Value
Infectious Diseases
Infectious Diseases By Value
Other Diseases
Other Diseases By Value
By mRNA type
Introduction
mRNA type By Value
COVID-19
By Value
Nucleoside-Modified mRNA (modRNA)
Nucleoside-Modified mRNA (modRNA) By Value
Unmodified mRNA
Unmodified mRNA By Value
Self-Amplifying mRNA
Self-Amplifying mRNA By Value
Non-COVID-19
By Value
Nucleoside-Modified mRNA (modRNA)
Nucleoside-Modified mRNA (modRNA) By Value
Unmodified mRNA
Unmodified mRNA By Value
Self-Amplifying mRNA)
Self-Amplifying mRNA) By Value
Germany
France
Spain
Italy
Russia
Nordic
Benelux
Rest of Europe
APAC Market Analysis
Introduction
By Applications
Introduction
Applications By Value
COVID-19 mRNA vaccines
By Value
Commercialized Vaccines
Commercialized Vaccines By Value
Pipeline Vaccines
Pipeline Vaccines By Value
Non-COVID-19 mRNA vaccines
By Value
Oncology
Oncology By Value
Infectious Diseases
Infectious Diseases By Value
Other Diseases
Other Diseases By Value
By mRNA type
Introduction
mRNA type By Value
COVID-19
By Value
Nucleoside-Modified mRNA (modRNA)
Nucleoside-Modified mRNA (modRNA) By Value
Unmodified mRNA
Unmodified mRNA By Value
Self-Amplifying mRNA
Self-Amplifying mRNA By Value
Non-COVID-19
By Value
Nucleoside-Modified mRNA (modRNA)
Nucleoside-Modified mRNA (modRNA) By Value
Unmodified mRNA
Unmodified mRNA By Value
Self-Amplifying mRNA)
Self-Amplifying mRNA) By Value
China
By Applications
Introduction
Applications By Value
COVID-19 mRNA vaccines
By Value
Commercialized Vaccines
Commercialized Vaccines By Value
Pipeline Vaccines
Pipeline Vaccines By Value
Non-COVID-19 mRNA vaccines
By Value
Oncology
Oncology By Value
Infectious Diseases
Infectious Diseases By Value
Other Diseases
Other Diseases By Value
By mRNA type
Introduction
mRNA type By Value
COVID-19
By Value
Nucleoside-Modified mRNA (modRNA)
Nucleoside-Modified mRNA (modRNA) By Value
Unmodified mRNA
Unmodified mRNA By Value
Self-Amplifying mRNA
Self-Amplifying mRNA By Value
Non-COVID-19
By Value
Nucleoside-Modified mRNA (modRNA)
Nucleoside-Modified mRNA (modRNA) By Value
Unmodified mRNA
Unmodified mRNA By Value
Self-Amplifying mRNA)
Self-Amplifying mRNA) By Value
Korea
Japan
India
Australia
Taiwan
South East Asia
Rest of Asia-Pacific
Middle East and Africa Market Analysis
Introduction
By Applications
Introduction
Applications By Value
COVID-19 mRNA vaccines
By Value
Commercialized Vaccines
Commercialized Vaccines By Value
Pipeline Vaccines
Pipeline Vaccines By Value
Non-COVID-19 mRNA vaccines
By Value
Oncology
Oncology By Value
Infectious Diseases
Infectious Diseases By Value
Other Diseases
Other Diseases By Value
By mRNA type
Introduction
mRNA type By Value
COVID-19
By Value
Nucleoside-Modified mRNA (modRNA)
Nucleoside-Modified mRNA (modRNA) By Value
Unmodified mRNA
Unmodified mRNA By Value
Self-Amplifying mRNA
Self-Amplifying mRNA By Value
Non-COVID-19
By Value
Nucleoside-Modified mRNA (modRNA)
Nucleoside-Modified mRNA (modRNA) By Value
Unmodified mRNA
Unmodified mRNA By Value
Self-Amplifying mRNA)
Self-Amplifying mRNA) By Value
UAE
By Applications
Introduction
Applications By Value
COVID-19 mRNA vaccines
By Value
Commercialized Vaccines
Commercialized Vaccines By Value
Pipeline Vaccines
Pipeline Vaccines By Value
Non-COVID-19 mRNA vaccines
By Value
Oncology
Oncology By Value
Infectious Diseases
Infectious Diseases By Value
Other Diseases
Other Diseases By Value
By mRNA type
Introduction
mRNA type By Value
COVID-19
By Value
Nucleoside-Modified mRNA (modRNA)
Nucleoside-Modified mRNA (modRNA) By Value
Unmodified mRNA
Unmodified mRNA By Value
Self-Amplifying mRNA
Self-Amplifying mRNA By Value
Non-COVID-19
By Value
Nucleoside-Modified mRNA (modRNA)
Nucleoside-Modified mRNA (modRNA) By Value
Unmodified mRNA
Unmodified mRNA By Value
Self-Amplifying mRNA)
Self-Amplifying mRNA) By Value
Turkey
Saudi Arabia
South Africa
Egypt
Nigeria
Rest of MEA
LATAM Market Analysis
Introduction
By Applications
Introduction
Applications By Value
COVID-19 mRNA vaccines
By Value
Commercialized Vaccines
Commercialized Vaccines By Value
Pipeline Vaccines
Pipeline Vaccines By Value
Non-COVID-19 mRNA vaccines
By Value
Oncology
Oncology By Value
Infectious Diseases
Infectious Diseases By Value
Other Diseases
Other Diseases By Value
By mRNA type
Introduction
mRNA type By Value
COVID-19
By Value
Nucleoside-Modified mRNA (modRNA)
Nucleoside-Modified mRNA (modRNA) By Value
Unmodified mRNA
Unmodified mRNA By Value
Self-Amplifying mRNA
Self-Amplifying mRNA By Value
Non-COVID-19
By Value
Nucleoside-Modified mRNA (modRNA)
Nucleoside-Modified mRNA (modRNA) By Value
Unmodified mRNA
Unmodified mRNA By Value
Self-Amplifying mRNA)
Self-Amplifying mRNA) By Value
Brazil
By Applications
Introduction
Applications By Value
COVID-19 mRNA vaccines
By Value
Commercialized Vaccines
Commercialized Vaccines By Value
Pipeline Vaccines
Pipeline Vaccines By Value
Non-COVID-19 mRNA vaccines
By Value
Oncology
Oncology By Value
Infectious Diseases
Infectious Diseases By Value
Other Diseases
Other Diseases By Value
By mRNA type
Introduction
mRNA type By Value
COVID-19
By Value
Nucleoside-Modified mRNA (modRNA)
Nucleoside-Modified mRNA (modRNA) By Value
Unmodified mRNA
Unmodified mRNA By Value
Self-Amplifying mRNA
Self-Amplifying mRNA By Value
Non-COVID-19
By Value
Nucleoside-Modified mRNA (modRNA)
Nucleoside-Modified mRNA (modRNA) By Value
Unmodified mRNA
Unmodified mRNA By Value
Self-Amplifying mRNA)
Self-Amplifying mRNA) By Value
Mexico
Argentina
Chile
Colombia
Rest of LATAM
Competitive Landscape
mRNA Vaccines and Therapeutics Market Share By Players
M&A Agreements & Collaboration Analysis
Market Players Assessment
Arcturus Therapeutics Holdings Inc
Overview
Business Information
Revenue
ASP
SWOT Analysis
Recent Developments
BioNTech SE
Daiichi Sankyo Company
CureVac N.V
Limited
ethris GmbH
GlaxoSmithKline plc
Gennova Biopharmaceuticals Ltd
Genova Biopharmaceuticals Ltd
Moderna Inc
Panthera Therapeutics GmbH
Providence Therapeutics
Silence Therapeutics
Research Methodology
Research Data
Secondary Data
Major secondary sources
Key data from secondary sources
Primary Data
Key data from primary sources
Breakdown of primaries
Secondary And Primary Research
Key industry insights
Market Size Estimation
Bottom-Up Approach
Top-Down Approach
Market Projection
Research Assumptions
Assumptions
Limitations
Risk Assessment
Appendix
Discussion Guide
Customization Options
Related Reports
Disclaimer
Purchase Benefits
Eligible for a free updated report next year
Completely customizable scope
30% discount on your next purchase
Dedicated account manager
Query resolution within 24 hours
Permission to print the report
We are featured on :
Sample Details
You will receive a link to download the sample pages on your email immediately after filling out a form
A sample report will help you understand the structure of our full report
The sample shared will be for our off-the-shelf market report
The off-the-shelf report is curated considering a broader audience for this market, we have insights extending well beyond the scope of this report. Please reach out to discuss
Should the sample pages not contain the specific information you seek, we extend the option to request additional details, which our dedicated team will incorporate.
The sample is free of cost, while the full report is available for a fee.